VTX 1849
Alternative Names: VTX-1849Latest Information Update: 28 Dec 2023
At a glance
- Originator Verseau Therapeutics
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Macrophage stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Solid tumours
Most Recent Events
- 28 Dec 2023 No recent reports of development identified for preclinical development in Solid-tumours in USA (Parenteral)